Premium
HLA‐DRB alleles are differentially expressed by tumor cells in breast carcinoma
Author(s) -
Oldford Sharon A.,
Robb J. Desmond,
Watson Peter H.,
Drover Sheila
Publication year - 2004
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.20441
Subject(s) - allele , breast carcinoma , immunohistochemistry , biology , hla dr , cd3 , immune system , tumor infiltrating lymphocytes , antibody , pathology , cancer research , carcinoma , immunology , breast cancer , medicine , antigen , gene , immunotherapy , cancer , genetics , cd8
The biologic and prognostic significance of HLA‐DR expression and T‐cell infiltration in breast carcinoma are presently controversial. To test the hypothesis that these factors are influenced by particular HLA‐DRB alleles, 52 breast tumor samples, composed of 26 DRB1*04 and 26 non‐DRB1*04 tumors, were assessed using immunohistochemistry for expression of DR and its associated invariant chain (Ii) and for infiltrating CD3 + T cells. While DR expression by tumor cells was significantly associated with T‐cell infiltration, DRB1*04 tumors were more frequently DR + Ii + and contained smaller CD3 + infiltrates than non‐DRB1*04 tumors. This difference was largely attributable to DRB1*07 tumors, which were typically DR − Ii − , although they contained similar numbers of T cells to DR + Ii + tumors. Further analysis of DR + tumors using allotype discriminating antibodies revealed that DRB1*04 alleles were always expressed, while non‐DRB1*04 alleles were inconsistently expressed. The results of this study provide the first reported evidence that DRB alleles influence DR expression and T‐cell infiltration in breast carcinoma and suggest that multiple factors contribute to DR expression. Ongoing studies aimed at elucidating the molecular and immunologic mechanisms controlling differential DR expression and implications for prognosis and outcome should further our understanding of the antitumor immune response and evasion strategies employed by tumor cells. © 2004 Wiley‐Liss, Inc.